Abstract
715TiP ARTS-021-1001: Phase I/II study of ARTS-021, a potent, oral administrated, selective CDK2 inhibitor, in advanced or metastatic solid tumors
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have